DGAP-News: VAXIMM AG / Key word(s): Conference 
VAXIMM to Participate at Upcoming Scientific and Industry Events 
2021-03-18 / 09:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
VAXIMM to Participate at Upcoming Scientific and Industry Events 
Basel (Switzerland) and Mannheim (Germany), March 18, 2021 - VAXIMM AG, a Swiss/German biotech company focused on 
developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide 
range of cancer-related antigens, announced today that the Company will participate in several scientific and industry 
events in the coming weeks. All conferences will be held virtually. 
15th Annual International Partnering Conference BIO-Europe Spring(R) 
March 22-25, 2021 
Dr. Heinz Lubenau, Chief Executive Officer and Co-Founder, will give a company presentation and participate in the 
online partnering system. To request a meeting, please sign up through the event's partneringONE meeting system. 
European Biotech Investor Days 2021 
April 7-8, 2021 
Dr. Lubenau will give a company presentation at 5pm CEST, 7 April, and be available for one-on-one meetings. 
American Association for Cancer Research (AACR) Annual Meeting 
April 10-15 and May 17-21, 2021 
Dr. Lubenau will attend the conference. To schedule a meeting with the Company, please contact [email protected] 
Alliance for Cancer Gene Therapy Summit 2021 
April 29, 2021 
Dr. Lubenau will attend the conference. To schedule a meeting with the Company, please contact [email protected] 
Upcoming events in which VAXIMM will participate are updated on a regular basis. See the Events section of the 
Company's website for more information. 
About VAXIMM 
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients 
suffering from cancer. VAXIMM's plug and play DNA vaccination technology is based on a live attenuated, safe, orally 
available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target a wide range 
of cancer-related antigens. The Company has a pipeline of complementary development candidates targeting different 
tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and 
certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in 
clinical development for several tumor types, including brain cancer. As part of a scientific collaboration with Merck 
KGaA, Darmstadt, Germany, and Pfizer Inc., VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with 
the human anti-PD-L1 antibody, avelumab. VAXIMM's neoantigen program is currently in preclinical development; the 
Company's platform allows for fast manufacturing of personalized T-cell cancer vaccines and may overcome key issues 
faced by other neoantigen approaches. A clinical Phase I basket study in collaboration with NEC Corporation is in 
preparation. VAXIMM also has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full 
rights in China and other Asian countries (excluding Japan) to VAXIMM's existing programs. 
VAXIMM's investors include: BB Biotech Ventures, BCM Europe, BioMed Partners, CMS, M Ventures, NEC and Sunstone 
Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in 
Mannheim, Germany, is responsible for the Company's development activities. For more information, please visit 
www.vaximm.com and follow us on LinkedIn. 
Contact: 
VAXIMM AG 
Dr. Heinz Lubenau 
Tel.: +49 621 8359 687 0 
Email: [email protected] 
Media Inquiries: 
MC Services AG 
EU: Katja Arnold 
USA: Laurie Doyle, Dr. Erica Fiorini 
Tel EU: +49 89 210228 0 
Tel USA: +1 339 832 0752 
Email: [email protected] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-03-18 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1176441 2021-03-18

(END) Dow Jones Newswires

March 18, 2021 04:31 ET (08:31 GMT)



Source link